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Maternal Race/Ethnicity and Postpartum
Diabetes Screening:
A Systematic Review and Meta-Analysis
Cynthia J. Herrick, MD, MPHS,1,2 Ritika Puri, MD,1 Rana Rahaman, MA,3 Angela Hardi, MLIS,4
Karyn Stewart, PhD,5 and Graham A. Colditz, MD, DrPH2
Abstract
Introduction: Fifty percent of women with gestational diabetes mellitus (GDM) may progress to type 2 diabetes
with highest risk among black women. This study aims to characterize postpartum diabetes screening rates
among U.S. women with GDM by racial and ethnic group to characterize potential disparities.
Materials and Methods: A standardized search of Ovid-Medline, Embase, Scopus, Cumulative Index of
Nursing and Allied Health Literature (CINAHL), Cochrane, ProQuest, and Clinicaltrials.gov was conducted
through October 12, 2018. Of 1,555 titles reviewed, 27 studies met inclusion criteria. Meta-proportion routines
with random-effects models estimated pooled postpartum screening proportion effect size (ES) with 95%
confidence interval (CI) by racial and ethnic group. Heterogeneity was measured using Cochrane’s Q and
Higgins I2 tests. Data were stratified by intervention and data source.
Results: There were 96,439 women, of whom 81,930 had race/ethnicity recorded. Heterogeneity was high
(I2 = 99.7%). Postpartum screening rates were low (pooled ES 42% [95% CI 35%–48%]). Point estimates for
pooled screening proportions were lower among white (pooled ES 35% [95% CI 28%–42%]) and black (pooled
ES 33% [95% CI 24%–42%]) women than among Hispanic (pooled ES 45% [95% CI 37%–53%]) and Asian
(pooled ES 50% [95% CI 41%–58%]) women. Interventions to improve screening were most common and
effective among Hispanic women.
Discussion: Postpartum screening for diabetes after GDM remains low, and black women have among the
lowest postpartum screening rates despite highest risk for type 2 diabetes progression. Reporting of race/
ethnicity, screening methods, and screening time frames varied across studies.
Conclusion: Future studies must standardize racial/ethnic data reporting and examine interventions that address
postpartum diabetes screening and prevention.
Keywords: gestational diabetes, race and ethnicity, postpartum diabetes screening, health disparities
Introduction
Gestational diabetes mellitus (GDM) complicates5%–9% of pregnancies in the United States, and risk
increases with age, body mass index (BMI), nonwhite race,
and lower socioeconomic status.1–4 One third of women with
GDM have persistent glucose abnormalities at 6–12 weeks
postpartum, and more than half may develop type 2 diabetes
during their lifetime.5–7 Furthermore, the risk of developing
type 2 diabetes appears to be highest among black women.4,8
Thus, GDM is associated with significant risk of future
chronic disease among young women, and postpartum
follow-up is critical.3,5
Type 2 diabetes screening after a pregnancy compli-
cated by GDM is critical because hyperglycemia, even
in a relatively asymptomatic patient, increases the risk for
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complications, such as neuropathy, retinopathy, and nephrop-
athy.9,10 Furthermore, impaired glucose metabolism increases
risk of maternal obstetric and child developmental complica-
tions in future pregnancies.5 With early detection of at risk
patients, lifestyle interventions and metformin can reduce the
risk for progression to type 2 diabetes by 50%.11–13
The American College of Obstetricians and Gynecologists
and the American Diabetes Association recommend diabetes
screening at 4–12 weeks postpartum and every 1–3 years
thereafter among women with GDM.3,5 Fasting plasma glu-
cose and the 2 hours 75 g oral glucose tolerance test (oGTT)
are acceptable tests in the 4–12 weeks postpartum, but the
oGTT is most sensitive. A hemoglobin A1C (Hb A1C) is ac-
ceptable for screening after 12 weeks postpartum.
However, estimates from prior studies suggest that rates of
screening are low, particularly in populations served by
Medicaid.14–17 A prior systematic review, including single
center studies and a single large prospective cohort study,
estimated median postpartum screening rates to be 48%
(range 34%–73%).14 Race was mentioned as one of many
factors that could affect screening rates, but this variation was
not systematically examined. In women on Medicaid during
pregnancy, receipt of recommended screening appears to be
under 10% in the first 12 weeks and under 20% at 1 year.15,17
Systematic reviews and meta-analyses quantify the rates of
progression to type 2 diabetes from GDM7,18 as well as the
recurrence of GDM.19 The utility of reminder systems for
screening after pregnancy is well documented20,21 as is the
sensitivity and specificity of different tests for screening.22,23
Another systematic review in 2013 stratified studies by
screening time frame and active intervention compared to
usual care, but again did not look specifically at variation by
race/ethnicity.24 Thus, while screening rates and strategies to
improve screening have been documented, there has not been
a systematic examination to date of screening rates and in-
terventions to improve screening across racial and ethnic
groups which is critical for addressing health disparities.25
In the current systematic review, we expand upon existing
reviews to include studies published after 2013, incorporat-
ing one large retrospective cohort study and several other
smaller studies, with a specific aim to describe racial and
ethnic differences in screening rates. To accomplish this
unique objective, we selected studies that specifically re-
ported screening rates by racial and ethnic group, and we
utilized meta-analysis techniques to determine how post-
partum diabetes screening rates vary by race/ethnicity among
women with a history of GDM in the United States.
Materials and Methods
This systematic review was registered on March 7, 2017 in
PROSPERO (CRD42017068383). The search strategy was
intentionally broad seeking to capture all literature that ad-
dressed any postpartum diabetes screening in women with
GDM. The initial search was not limited to studies that ad-
dressed U.S. populations or racial and ethnic disparities be-
cause there were concerns that this would eliminate studies
with race data in the full text that were not highlighted in titles
and abstracts. Prospective and retrospective cohort studies,
cross-sectional studies, case–control studies, and randomized
controlled trials were considered for inclusion. Case reports,
case series, and abstracts were excluded.
Published and gray literature was searched using strategies
designed by a medical librarian for the concepts of GDM
and postpartum diabetes screening. These strategies were es-
tablished using a combination of standardized terms and
keywords, and were executed in Ovid Medline 1946-, Embase
1947-, Scopus 1823-, Cumulative Index of Nursing and Allied
Health Literature (CINAHL) 1937-, Cochrane Database of
Systematic Reviews, Cochrane Register of Controlled Trials,
Database of Abstracts of Reviews of Effects, ProQuest Dis-
sertations and Theses, and Clinicaltrials.gov. Database-
supplied English language limits were applied.
Search terms included variations and combinations of the
following terms: gestational diabetes, pregnancy-induced
diabetes, pregnancy diabetes, diabetes mellitus gravidarum,
postpartum period, puerperium, puerperal, postdelivery,
postnatal, glucose tolerance test, fasting plasma glucose, oral
glucose tolerance, glycemic, HbA1C, A1C, and hemoglobin
A1C. Full search strategies for each database are delineated
in Supplementary Data S1. All searches were initially com-
pleted in February 2017 and updated in October 2018 with
results exported to EndNote. Automated duplicate finding
was used and 1339 duplicates were assumed to be accurately
identified and removed for a total of 1555 citations. Manual
review of the reference list for each incorporated study was
completed to identify any studies missing from our search
strategy. Institutional Review Board approval was not re-
quired for this systematic review and meta-analysis of dei-
dentified published data.
Two authors individually reviewed titles and abstracts
against inclusion and exclusion criteria. Full text articles
were retrieved where necessary to further evaluate relevant
articles for inclusion. As differences by race and ethnicity are
likely unique to each country and this was the focus of our
review, only studies performed in the United States were
included in the final review and meta-analysis. Non-U.S.
studies were excluded at the title and abstract review stage if
it was possible to identify study location. Studies that dis-
cussed postpartum screening but did not include sufficiently
stratified publicly available race/ethnicity data were excluded
at the full-text review stage.
Of the 1,555 citations derived with the above search
strategy, a further 298 studies were excluded because they
were animal studies, duplicates, studies on an unrelated topic,
or not in English. The remaining 1,257 abstracts were re-
viewed and a total of 1,197 studies were excluded because
they were abstract only, case reports, commentaries/errata,
guidelines, reviews, systematic reviews, non-U.S. population-
based studies, qualitative studies, and studies for which no
information on postpartum screening rates was available.
Sixty articles were obtained for full-text review. Additional
studies were excluded because there were no stratified
race/ethnicity data for screening rates or because the same
cohort had been used in a previously included study. Ulti-
mately, 27 articles met inclusion criteria and contributed
data to the analysis.15,26,31,32–51 Three of the studies were
divided into intervention and non-intervention groups in
the meta-analysis.39,41,42 Figure 1 illustrates the PRISMA
diagram for study selection.
Abstracted data included publication year, data collection
time frame, data source (electronic medical record [EMR],
laboratory data warehouse, survey, and administrative
claims), study setting and location, study method, method for















































identifying GDM, and the time frame for postpartum screening
assessment. In addition, it was noted if an intervention to im-
prove screening was studied and if only recommended
screening tests or all tests were considered. Finally, total
numbers of women with GDM and total numbers of women
with GDM who were screened for diabetes postpartum both
overall and within each racial and ethnic group (white, black,
Hispanic, Asian, and other) were abstracted. To standardize
our data collection, when screening percentages were pre-
sented between racial and ethnic groups, we calculated
screening rates within racial and ethnic groups. A template for
data extraction is presented in Supplementary Data S2.
As the exposure of interest for our review, we collected the
method by which race and ethnicity were assessed (self-
report, birth certificate, medical record extraction, geo-
graphic variables, or not reported). Studies were examined
for assessment of confounding, and when assessed, incor-
porated confounders were extracted. Study quality was also
assessed using the 14 question Quality Assessment Tool for
Observational Cohort and Cross-Sectional Studies from the
National Heart, Lung, and Blood Institute (NHLBI) (Sup-
plementary Table S1).
This tool assesses study quality indicators such as pre-
specification of the research question and population, inclusion
of >50% of eligible participants, utilization of inclusion and
exclusion criteria, and sample size justification. It also con-
siders assessment of exposure before outcome, time frame
sufficient for outcome assessment, exposure and outcome
measurement validity and consistent application, outcome as-
sessor blinding, <20% loss to follow-up, and confounder as-
sessment. Questions on this tool related to exposure dose and
frequency were not applicable to our research question con-
sidering race and ethnicity as the exposure.
All analyses were performed using Stata 15.1 (College
Station, TX). A meta-analysis of proportions (routine meta-
prop) was utilized to combine proportion estimates across
studies and approximate a pooled proportion effect size with
95% confidence interval (CI) for postpartum screening in the
overall population and each racial and ethnic group. The
effect of intervention to improve screening was examined
through stratification of analyses by populations in inter-
vention and nonintervention groups. Stratified analyses are
also presented according to data source (EMR vs. other
[administrative claims, laboratory data warehouse, or sur-
vey]). Heterogeneity was assessed using the Cochran’s Q and
Higgins I2 statistic. Given substantial heterogeneity between
studies, a random effects model was appropriate. Publication
bias was assessed utilizing a funnel plot and Begg and Eg-
ger’s tests for small study effects. In addition, a sensitivity




The publication dates of the studies included in this sys-
tematic review and meta-analysis range from 2006 to 2018,
representing deliveries from 1995 to 2016. Table 1 summa-
rizes study characteristics, including author, year and study
data sources, setting, and location. There were no randomized
controlled studies and most included studies were retro-
spective cohorts. Studies differed in the way GDM was
identified (Table 1, column 4). In most studies, GDM diag-
nosis was established by a 3 hours oGTT that met either the
Carpenter-Coustan criteria or National Diabetes Data Group
criteria (NDDG) or by coding from the International Clas-
sification of Diseases, 9th Revision (ICD-9). Some studies
used ICD-9 classification combined with medication or test
strip prescription. Other studies only specified medical chart
review or use of procedure codes for prenatal glucose
screening for GDM (CPT 82950 or 82951), and survey
studies utilized self-report to identify GDM.
FIG. 1. Flowchart
depicting selection of studies
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In addition to identifying GDM in different ways, studies
included in the meta-analysis also differed regarding size of
the population with GDM. The total number of women with
GDM in the studies included in our meta-analysis was
96,439. Race and ethnicity data were available on 81,930 of
these women. Study populations ranged from 58 to 32,253
women with GDM. Nineteen studies did not include an in-
tervention,15,26,27,29–31,33–38,40,43,44,47–49,51 five had only an
intervention arm,28,32,45,46,50 and three studies had both
nonintervention and intervention arms.39,41,42 Interventions
varied and included nurse education,41,42 reminder
calls,45,46,50 home glucose testing,28 nurse case manage-
ment,32 and Centering Pregnancyª group prenatal care.39
Two studies in the meta-analysis utilized claims data,15,30
one study used a large laboratory data warehouse,27 two
studies utilized national survey data,36,47 and others used
EMR data from single, predominantly academic, medical
centers, or integrated health systems (Table 1, column 3).
Four studies had only privately insured patients,28–31 one had
Medicaid only15 and others had a mix of payer sources or
failed to report this variable. Maternal age, parity, insurance
status, education, BMI, postpartum visits, and diabetes
medication use in pregnancy were commonly collected
confounders among the included studies. Among the studies
that reported attendance at the postpartum visit, all reported
attendance rates ‡70% (Table 1, column 6).
Study quality as assessed by the NHLBI quality as-
sessment tool was generally fair to good. All studies had
defined the research question, specified the population
under study, clearly applied inclusion and exclusion cri-
teria, and had exposure assessed before outcome (for
noncross-sectional studies). While all studies collected at
least some demographic and clinical information that
could be considered confounders, six studies did not in-
clude a method, such as multivariable regression, to di-
rectly assess the effect of confounders on the screening
outcome.28,32,42,45,46,50 Four studies had <50% of the eli-
gible population participating27,37,43,46 and three did not
specify how many women were eligible.42,45,50 Loss to
follow-up was <20% in 11 of the 24 studies that were not
cross-sectional.15,26,29,30,33,34,37,39,44,48,49 Only five stud-
ies did an a priori sample size calculation,38,43,45,46,49 and
assessors were not blinded to outcome in any study. Only
two studies included a self-reported postpartum screening
outcome.36,47 All other outcomes were laboratory results
documented in medical records or administrative codes for
laboratories completed. Race and ethnicity were typically
self-reported or extracted from birth certificate or medical
records. One study utilized a method to estimate racial and
ethnic distribution in the sample through geographic in-
formation systems,30 and four studies did not record how
race and ethnicity were assessed.27,36,37,51
Findings
Overall, postpartum screening rates for diabetes after a
pregnancy complicated by GDM were low. As shown in
Table 2, the pooled proportion estimate of screening among
all women with GDM was 42% (95% CI 35%–48%).
Screening rates were relatively low among individual racial
and ethnic groups as well. The overall pooled proportion
estimates of screening among different racial and ethnic
groups follow: white 35% (95% CI 28%–42%), black 33%
(95% CI 24%–42%), Hispanic 45% (95% CI 37%–53%),
Asian 50% (95% CI 41%–58%), and other 36% (95% CI
27%–45%) (Table 2). Point estimates for screening were at
least 10% higher in Asian and Hispanic populations than in
white and black populations, although CIs overlapped.
Studies in which there was an intervention to improve
screening reported higher pooled proportions screened 56%
(95% CI 44%–66%) than those without intervention 37%
(95% CI 30%–44%) (Fig. 2). When data were stratified by
intervention and no intervention, only Hispanic women dem-
onstrated a significant effect of intervention on pooled propor-
tion estimates of screening (intervention 68% [95% CI 54%–
81%] vs. nonintervention groups 37% [95% CI 29%–45%]).
Table 2. Pooled Estimates of Postpartum Diabetes Screening by Race and Ethnicity
from Metaproportion Routines
Overall
Sensitivity analysis (Studies with

















screening ES (95% CI)
Totala 27 96,439 0.42 (0.35–0.48) 19 95,643 0.42 (0.35–0.50)
White 22 36,807 0.35 (0.28–0.42) 16 36,547 0.33 (0.25–0.40)
Black 22 7,315 0.33 (0.24–0.42) 15 7,117 0.33 (0.23–0.44)
Hispanic 21 18,336 0.45 (0.37–0.53) 15 18,148 0.44 (0.36–0.52)
Asian 17 12,269 0.50 (0.41–0.58) 12 12,184 0.48 (0.39–0.57)
Otherb 12 6,351 0.36 (0.27–0.45) 9 6,312 0.36 (0.27–0.46)
aOza-Frank36 was only included in the total. Although screening rates were reported for racial and ethnic groups, exact numbers to
calculate screening rate were only reported on the total.
bStudies included in the meta-analysis of proportions for the ‘‘Other’’ racial and ethnic group must have specified screening rates for all
four racial and ethnic groups (white, black, Hispanic, and Asian), such that the ‘‘Other’’ group would not include information about
screening in any of these groups. There were 10 studies that had data for an ‘‘Other’’ group (including a total of 852 women) that did not
have data stratified for all white, black, Hispanic, and Asian populations as well and are not included in the meta-analysis here. This
discrepancy accounts for the 1% of the population not represented in this table.
CI, confidence interval; ES, effect size.















































FIG. 2. Forest plots depicting pooled proportions for postpartum diabetes screening in each racial and ethnic group (A:
















































FIG. 3. Forest plots depicting pooled proportions for postpartum diabetes screening in each racial and ethnic group (A:
Total, B: White, C: Black, D: Hispanic, E: Asian, F: Other Race), stratified by data source (EMR vs. other [administrative
















































There were also more studies reporting on interventions in
Hispanic women than any other group (eight intervention
studies among Hispanic women,28,32,39,41,42,45,46,50 five for
white and black women,28,41,45,46,50 four for Asian wom-
en,28,41,46,50 and three for other racial and ethnic groups).28,46,50
Other racial and ethnic subgroups did not demonstrate consis-
tent effects of intervention on screening. Studies with inter-
ventions to improve screening are reported in Table 1 with
information about type of intervention and screening point
estimates by racial and ethnic group. A meta-analysis of in-
tervention effect in the three studies with a control arm was not
possible given heterogeneity. Stratification by study quality,
study design, method for identifying GDM, or screening
time frame did not result in differences in pooled proportion
screened overall or in any racial and ethnic subgroup.
Overall, studies using the EMR as the data source had a
pooled proportion of women screened of 45% (95% CI 40%–
50%) compared with 27% (95% CI 17%–38%) in studies
using other data sources (administrative claims, laboratory
data warehouse, survey). As these CIs do not overlap, it can
be concluded that this is a statistically significant differ-
ence. Significant differences between screening rates by data
source were present for white, Hispanic, and other racial and
ethnic groups (Fig. 3).
Heterogeneity and publication bias are important consider-
ations when assessing the validity of our findings. The I2 value
generated for the total population is quite high at 99.7%, in-
dicating that the variability in results is attributable to variation
between studies. The same was true of the I2 for each racial and
ethnic group. With stratification by intervention versus nonin-
tervention, heterogeneity was lower in the intervention stratum
among racial and ethnic subgroups (31%–88%). Visual in-
spection of a funnel plot was largely symmetrical implying low
risk of publication bias (Supplementary Fig. 1). Begg and
Egger’s tests also demonstrated no small study effects. In a
sensitivity analysis including only studies with 200 or more
participants, pooled proportion estimates for screening were
not appreciably different overall or in each racial and ethnic
group (Table 2).15,27,29–36,38–41,43,44,47,49,51
Discussion
Postpartum screening rates for type 2 diabetes in a popu-
lation of women with a history of GDM are low among all
racial and ethnic groups. Guidelines recommend that women
should be screened at multiple intervals after a pregnancy
with GDM, and less than half of women in reported studies
are being screened. There were also very few studies incor-
porating black women in interventions intended to improve
screening rates. Overall, black women were screened at lower
rates than Hispanic and Asian women and similar rates to
non-Hispanic white women. This disparity must be addressed
in future studies, particularly as black women are at highest
risk for progression to type 2 diabetes after a pregnancy with
GDM.4,8 In addition, disproportionate maternal mortality and
morbidity among black women in the United States is a
critical public health problem, highlighting the need for
particular focus on care for this population during and after
pregnancy.52
Hispanic women also have a high risk for progression to
type 2 diabetes after pregnancy with GDM, and more studies
have been conducted utilizing interventions to improve
screening among Hispanic women than any other racial and
ethnic group. These interventions, particularly higher inten-
sity interventions like Centering Pregnancyª, significantly
increased screening among Hispanic women and should be
implemented and studied at larger scale and among other
racial and ethnic groups.32,39,42
To our knowledge, this is the first systematic review to
specifically examine racial and ethnic variation in postpartum
diabetes screening rates. In addition, our analysis is unique in
that metaproportion routines were utilized to estimate pooled
proportion estimates. CIs overlapped; however, point esti-
mates for pooled screening rates were at least 10% higher
among Asian and Hispanic women than among white and
black women. There were a larger number of studies with
interventions to improve screening among Hispanic women,
and when point estimates for pooled screening proportions
were compared among nonintervention groups, these esti-
mates were similar for white, black, and Hispanic women.
Nonetheless, even in nonintervention groups, the point esti-
mate for postpartum screening among Asian women was
about 10% higher. It is important to recognize both the low
overall screening rates and this discrepancy by race and
ethnicity as black and Hispanic women are the most likely to
progress to type 2 diabetes after GDM.
Our study addresses variation in screening rates reported
utilizing different data sources. Studies reporting screening
rates from EMR data had pooled proportions for screening
that were statistically significantly higher than studies using
administrative claims, laboratory data warehouse, or survey
data. While this is understandable given the more detailed
nature of the EMR and ability to access laboratory results, it is
difficult to capture this type of data on the state or national
level in the United States as medical record systems vary
across clinics and hospital systems. Hence, EMR data reflect
screening rates in single, often academic, centers and inte-
grated health systems. With advances in information tech-
nology and the establishment of practice-based research
networks, future research can focus on connecting EMR
systems to capture more accurate screening data across mul-
tiple systems in routine care. In addition, future research may
focus on development and evaluation of EMR-based inter-
ventions aimed at improving diabetes screening rates as well.
This systematic review and meta-analysis has a number of
limitations. There was substantial heterogeneity among studies.
Sources of heterogeneity may include different study designs
and incorporation of interventions to improve screening, study
quality, data sources, race/ethnicity classification, time frame,
and test used for postpartum screening. We felt it was important
to report a pooled screening estimate, despite heterogeneity, to
demonstrate in a rigorous way, across many different studies,
that screening rates are low across all racial and ethnic groups.
Reporting pooled estimates with recognition of heterogeneity
among studies can motivate standardization of future random-
ized studies in this field. Utilizing stratification and metare-
gression, the heterogeneity was not consistently explained by
data source, intervention, use of a recommended test, method
for identifying GDM, study quality, study design, or screening
time frame.
In addition, a large number of studies were eliminated at
the full text review stage because they did not present
screening rates stratified by racial and ethnic group. This may
have been related to low numbers of underrepresented















































minorities or inconsistent reporting of screening rates. Some
of these excluded studies controlled for race and ethnicity in
multivariable regression models assessing associations with
screening, but this was typically done using a dichotomous
race variable (e.g., white vs. nonwhite). Future research should
incorporate screening data by race and ethnicity in an easily
accessible manner, particularly as the National Institutes of
Health increases the focus on rigor and reproducibility.
Additional challenges were associated with data collec-
tion/reporting and definitions of key variables. Studies
varied in the way race and ethnicity were defined (self-
report, medical record extraction, birth certificate records,
and geographic estimates), and some studies did not report
how race and ethnicity were collected. There was a lack of
consistency among studies in reporting of data for ra-
cial/ethnic groups. Some studies reported specific screening
on 4–5 groups (white, black, Hispanic, Asian, and other),
while other studies incorporated only one group and still
others divided data into white and nonwhite populations.
For the purposes of reporting pooled proportions, we only
reported pooled proportions for the ‘‘Other’’ racial/ethnic
category if the study included specific screening rates on
white, black, Hispanic, and Asian populations, so as to limit
the inadvertent inclusion of these racial and ethnic groups in
the ‘‘Other’’ category.
In addition, both GDM diagnosis and outcome definition
varied among studies. Addressing the outcome of postpartum
screening specifically, studies varied regarding the time
frame of postpartum screening as well as the type of testing
completed. While a minority of studies had <50% of the
eligible population participating, many had >20% loss to
follow-up, contributing to the possibility for selection and
ascertainment bias. In addition, studies did not report dif-
ferences in attendance of the postpartum office visit stratified
by race/ethnicity so this could contribute to differences in
reported screening rates among racial and ethnic groups.
However, the overall percent of women attending at least
one postpartum visit was much higher than the percent of
women with postpartum diabetes screening, so postpartum
visit attendance likely explains only a small amount of this
variation.
Despite the challenges and limitations of this current sys-
tematic review and meta-analysis, it highlights the need for
additional research that can have a meaningful impact. Wo-
men often utilize their obstetrician and gynecologist for pri-
mary care in the childbearing years, hence, these health care
providers are frequently the first-line for postpartum diabetes
screening in the first 12 weeks and 1 year postpartum. Our
study serves as a call to action for researchers and clinicians
to work toward addressing barriers to postpartum diabetes
screening among all women.
Conclusion
Our findings are consistent with previous work that has
demonstrated low rates of postpartum diabetes screening
overall. Greater effort must be directed toward standardizing
the measurement, collection, and reporting of racial and
ethnic data in screening studies. Given the low screening
rates documented among all racial and ethnic groups, and the
high burden of subsequent type 2 diabetes and its compli-
cations, well-designed studies to examine interventions that
comprehensively address the needs of women in the post-
partum period are urgently needed. Increasing postpartum
screening for diabetes and enhancing prevention of type 2
diabetes among high risk women are essential next steps to
achieving health equity.
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